Each 5ml (one teaspoonful) of the reconstituted suspension contains Cefuroxime Axetil USP equivalent to Cefuroxime 152mg.

Cefuroxime Axetil is an oral prodrug of the bactericidal cephalosporin antibiotic Cefuroxime, which is resistant to most beta-lactamases and its active against a wide range of gram-positive and gram-negative organisms.

Cefuroxime Axetil owes its in vivo bactericidal activity to the parent compound. Cefuroxime is a well-characterized and effective antibacterial agent which has a broad-spectrum bactericidal activity against a wide range of common pathogens, including beta-lactamase-producing stains. Cefuroxime has good stability to bacterial beta-lactamase and consequently, is active against many ampicillin-resistant and amoxicillin-resistant strains. The bactericidal action of Cefuroxime results from inhibition of cell-wall synthesis by binding to essential target proteins.

After oral administration, Cefuroxime Axetil is absorbed form the gastrointestinal tract and rapidly hydrolyzed in the intestinal mucosa and blood to release Cefuroxime into the circulation. Peak serum Cefuroxime levels occur approximately two to three hours after oral dosing.

The serum half-life is about 1.2 hours. Approximately 50% serum Cefuroxime is protein bound.

Cefuroxime is not metabolised and is excreted by glomerular and tubular secretion.

Cefuroxime Axetil for oral suspension indicated for the treatment of infections caused by sensitive bacteria. Cefuroxime - Axetil is available in dry sryup30ml/60ml and 70ml and 100ml HPDE bottle containing powder.

Each vial contains Cefuroxime Sodium USP equivalent to Cefuroxime 750mg/1.5g.

Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration.

Cefuroxime has invitro activity against a wide-range of gram-positive and gram-negative organisms and it is highly stable in the presence of beta-lactamases of certain gram negative bacteria. The bactericidal action of Cefuroxime results from inhibition of cell-wall synthesis.

The serum half-life after either IM or IV injection is approximately 80 minutes. Approximately 89% of a dose of Cefuroxime is excreted by the kidneys over an 8 hour period, resulting in high urinary concentrations. Cefuroxime is detectable in therapeutic concentrations in pleural fluid, joint fluid, bile, sputum, bone and aqueous humor. Cefuroxime is 50% bound to serum proteins.

Cefuroxime Injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases.

Zocef Injection is available in 750mg/1.5g Cefuroxime per vial.

Each film-coated tablet contains Cefuroxime Axetil EP equivalent to Cefuroxime 250mg or 500mg.

Cefuroxime Axetil is the 1-acetoxyehyl ester of Cefuroxime. Cefuroxime is a semi synthetic analog of cephalosporin C. Cefuroxime has in vitro activity against a wide range of gram-positive and gram-negative organisms and its highly stable in the presence of beta-lactamases of certain gram negative bacteria. The bactericidal action of Cefuroxime results from inhibition of cell-wall synthesis.

Approximately 50% of serum Cefuroxime is bound to protein.

After oral administration, Cefuroxime Axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to Cefuroxime.

Cefuroxime is subsequently distributed throughout the extracellular fluids. The Axetil moiety is metabolized to acetaldehyde and acetic acid.

Cefuroxime tablets are indicated for the treatment of:-

• Upper and lower respiratory tract infections
• Skin and soft tissue infections
• Urinary tract infections etc.

Cefuroxime tablets are available in blister strip of 10 tablets.

Each Taxim vial contains Cefotaxime Sodium USP equivalent to Cefotaxime 250mg/500mg/1gm.

Taxim (Cefotaxime) injection is a semi synthetic, broad spectrum cephalosporin antibiotic. It is an odourless, white to slightly cream coloured powder. Taxim is freely soluble in water, insoluble in organic solvents.

IM- administration of a single 5700mg to normal volunteers mean peak serum concentrations of 11.7ug/ml was attained within 30 minutes and declined with an elimination half-life about 1 hour. About 60% of the administered dose was recovered from urine during the first 6 hours following the start of the infusion.

About 20-36% of I.V. administered during 14- Cefotaxime is secreted by the kidneys as unchanged. Cefotaxime and 15-25% as the desactyl derivative. It has shown to contribute the bactericidal activity.  

Taxim is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated micro-organisms.

Taxim Injection is available in 250mg/500mg/1g vial in a carton with 5ml ampoule of water for injection.